TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings

Table 1

Clinical and laboratory characteristic of 98 MPNs at diagnosis according to diagnosis.

	IMF	MPN-U	PV	TE	𝑃 value
Number of patients	9	8	26	55	na
M/F	8/1	3/5	17/9	25/30	0.04
Median age, years (range)	68 (54–82)	69 (43–67)	72 (30–85)	63 (25–89)	0.04
Follow-up days, median (range)	885.5 (397–2130)	1314 (350–2707)	1358.5 (128–5871)	2137 (179–4708)	0.1
Hb, g/100 mL (range)	15.1 (12.1–17.4)	16.1 (12.5–19.1)	18.0 (14.5–21.5)	14.9 (11.1–18.1)	0.0001
WBC × 10^9/L (range)	7.43 (5.52–13.82)	7.73 (5.4–15.53)	10.98 (1.7–19.6)	8.3 (3.18–16.71)	0.05
Monocytes × 10^9/L (range)	0.48 (0.08–0,89)	0.4 (0.3–0.82)	0.45 (0.02–1.55)	0.45 (0.11–0.78)	0.8
Plt × 10^9/L (range)	615 (429–1094)	629 (181–1006)	481 (134–1745)	684 (443–1750)	0.0001
JAK2 V617F 𝑛 (%)	6/9 (66.6)	6/8 (75)	26/26 (100)	35/55 (63.6)	0.0001
JAK2 V617F burden median % (range)	40 (5–64)	17 (4–40)	60 (24–90)	14 (5–59)	0.0001
EEC 𝑛 (%)	6/9 (66.6)	6/8 (75)	23/26 (88.5)	41/55 (74.5)	0.1
CGU-MK 𝑛 (%)	3/9 (33.3)	4/8 (37.5)	16/26 (61.5)	36/55 (65.5)	0.1
CD34 + SP × 10^9/L (range)	0.051 (0.013–0.25)	0.021 (0.0046–0.051)	0.040 (0.0035–0.5)	0.024 (0.0015–0.61)	0.07
CD34 + SP (%) (range)	0.05 (0.035–0.45)	0.03 (0.01–0.09)	0.04 (0.01–0.56)	0.03 (0.0015–0.27)	0.07
Bone marrow cellularity % (range)	60 (30–90)	40 (20–80)	80 (60–95)	50 (20–98)	0.0001
Single cytogenetic abnormality (𝑛)	1/9	2/8	2/26	0/54	0.3
Complex karyotype (𝑛)	0/9	0/8	0/26	1/54
Trisomy (𝑛)	0/9	0/8	1/26	0/54
Palpable splenomegaly (𝑛)	6/9	3/8	16/26	15/55	0.7
Splenic square cm^2 (range)	50 (26–102)	43,5 (37–65)	63 (25–200)	40 (28–105)	0.04
Arterial thromboses (𝑛)	5/9	0/8	6/26	12/55	0.6
Venous thromboses (𝑛)	1/9	0/8	6/26	3/55
Spontaneous haemorrhage (𝑛)	0/9	0/8	1/26	1/55	0.7
Posttraumatic haemorrhage (𝑛)	1/9	0/9	0/26	1/55
Cytoreductive treatment (𝑛)	7/9	7/8	26/26	42/55	0.06